Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

21.4%

3 terminated/withdrawn out of 14 trials

Success Rate

70.0%

-16.5% vs industry average

Late-Stage Pipeline

7%

1 trials in Phase 3/4

Results Transparency

0%

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
1(100.0%)
1Total
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (14)

Showing 14 of 14 trials
NCT06786130Terminated

Societal Burden Associated With Type 1 Diabetes in Canada

Role: lead

NCT06311864Completed

Real-World Observational Study on Patient-Reported Outcomes in the Treatment of Insomnia With Daridorexant in Canada

Role: lead

NCT07267091Completed

The Burden of Lupus in Canada From a Patient Perspective: A Canadian Real-World PROxy Study

Role: lead

NCT07323394Not Yet Recruiting

Real-World Study on the Impact of Atopic Dermatitis From a Caregiver Perspective

Role: lead

NCT07323303Not Yet Recruiting

Real-World Study on the Burden of Hidradenitis Suppurativa

Role: lead

NCT07035067Enrolling By Invitation

Multidimensional Burden of Platinum Resistant Ovarian Cancer (PROC) on Patients and Caregivers in Canada

Role: lead

NCT06610045Completed

The Burden of Multiple Myeloma on Patients and Caregivers Quality of Life: a Canadian Real-World Study

Role: lead

NCT05556564Completed

The Impact of Migraine on Canadians' Productivity: A Real-World Pharmacy-Based Study

Role: lead

NCT03640650Phase 4Terminated

Economic Impact of Dropless Therapy Versus Usual Care for Cataract Surgery: A Real-World Study.

Role: lead

NCT02228421Terminated

Study to Evaluate Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients

Role: lead

NCT02315365Completed

Real-World Outcome Research Study on Quality of Life, Work Productivity and Health Care Resource Utilization in Metastatic Breast Cancer

Role: lead

NCT02139215Completed

Study to Evaluate Real-world Pharmacoeconomics of Panitumumab in Metastatic Colorectal Cancer Patients

Role: lead

NCT02135757Completed

Study to Evaluate Real-world Pharmacoeconomics and Resistance Mechanisms of Panitumumab in Metastatic Colorectal Cancer Patients

Role: lead

NCT02041468Unknown

Study to Evaluate Resistance Mechanisms and Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients

Role: collaborator

All 14 trials loaded